{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:28:02Z","timestamp":1791041282994,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T00:00:00Z","timestamp":1445558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T00:00:00Z","timestamp":1445558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2015.86","type":"journal-article","created":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T09:21:49Z","timestamp":1445592109000},"page":"e362-e362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma"],"prefix":"10.1038","volume":"5","author":[{"given":"H","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Maeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,23]]},"reference":[{"key":"BFbcj201586_CR1","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383\u20133389.","journal-title":"J Clin Oncol"},{"key":"BFbcj201586_CR2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood.V124.21.145.145","volume":"124","author":"MJ Rummel","year":"2014","unstructured":"Rummel MJ, Balser C, Kaiser U, B\u00f6ck HP, Stauch MB, Heider A et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent, or mantle cell lymphomas \u2013 8-year follow-up results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Blood 2014; 124: 145.","journal-title":"Blood"},{"key":"BFbcj201586_CR3","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/j.1349-7006.2010.01635.x","volume":"101","author":"K Ohmachi","year":"2010","unstructured":"Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010; 101: 2059\u20132064.","journal-title":"Cancer Sci"},{"key":"BFbcj201586_CR4","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123: 2944\u20132952.","journal-title":"Blood"},{"key":"BFbcj201586_CR5","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203\u20131210.","journal-title":"Lancet"},{"key":"BFbcj201586_CR6","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00277-014-2135-8","volume":"93","author":"R Garc\u00eda Mu\u00f1oz","year":"2014","unstructured":"Garc\u00eda Mu\u00f1oz R, Izquierdo-Gil A, Mu\u00f1oz A, Roldan-Galiacho V, Rabasa P, Panizo C . Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol 2014; 93: 1879\u20131887.","journal-title":"Ann Hematol"},{"key":"BFbcj201586_CR7","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00280-013-2112-2","volume":"71","author":"RM Layman","year":"2013","unstructured":"Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB et al. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemother Pharmacol 2013; 71: 1183\u20131190.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbcj201586_CR8","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","volume":"31","author":"K Ohmachi","year":"2013","unstructured":"Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2013; 31: 2103\u20132109.","journal-title":"J Clin Oncol"},{"key":"BFbcj201586_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00277-014-2182-1","volume":"94","author":"T Hasegawa","year":"2015","unstructured":"Hasegawa T, Aisa Y, Shimazaki K, Nakazato T . Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma. Ann Hematol 2015; 94: 515\u2013517.","journal-title":"Ann Hematol"},{"key":"BFbcj201586_CR10","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3109\/10428194.2012.739285","volume":"54","author":"T Hosoda","year":"2013","unstructured":"Hosoda T, Yokoyama A, Yoneda M, Yamamoto R, Ohashi K, Kagoo T et al. Bendamustine can severely impair T-cell immunity against cytomegalovirus. Leuk Lymphoma 2013; 54: 1327\u20131328.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201586_CR11","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3109\/10428194.2010.551573","volume":"52","author":"U Tapan","year":"2011","unstructured":"Tapan U, May SK, Fiore J, Kozyreva O . Reactivation of hepatitis B virus following bendamustine-containing chemotherapy in a patient with multiple myeloma. Leuk Lymphoma 2011; 52: 916\u2013918.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201586_CR12","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3109\/10428194.2010.506569","volume":"51","author":"K Hashimoto","year":"2010","unstructured":"Hashimoto K, Kobayashi Y, Asakura Y, Mori M, Azuma T, Maruyama D et al. Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy. Leuk Lymphoma 2010; 51: 1816\u20131821.","journal-title":"Leuk Lymphoma"}],"updated-by":[{"DOI":"10.1038\/bcj.2017.100","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T00:00:00Z","timestamp":1509667200000}}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201586.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201586","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201586.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T05:03:08Z","timestamp":1672894988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,23]]},"references-count":12,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10]]}},"alternative-id":["BFbcj201586"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2015.86","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,23]]},"assertion":[{"value":"23 October 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DM received Lecture\u2019s fee from Honoraria from Eisai Co., Ltd. YK received research funding from Boehringer, Otsuka and Ariad. KT received research funding from Eisai, Symbio, Zenyaku Kogyo and Chugai Pharmaceutical. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}